Tyra Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Tyra Biosciences wird ein Gewinn- und Umsatzwachstum von 9.4% bzw. 74.3% pro Jahr prognostiziert, während der Gewinn pro Aktie um 14% pro Jahr wachsen soll.

Wichtige Informationen

4.8%

Wachstumsrate der Gewinne

13.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	80.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	19 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Aug 29

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Jul 21

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Mar 31

Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth

Dec 15

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:TYRA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2	-144	-86	N/A	5
12/31/2025	N/A	-121	-121	N/A	6
12/31/2024	N/A	-88	-86	N/A	6
6/30/2024	N/A	-81	-64	-63	N/A
3/31/2024	N/A	-75	-63	-62	N/A
12/31/2023	N/A	-69	-51	-50	N/A
9/30/2023	N/A	-59	-49	-49	N/A
6/30/2023	N/A	-51	-44	-44	N/A
3/31/2023	N/A	-52	-52	-51	N/A
12/31/2022	N/A	-55	-51	-50	N/A
9/30/2022	N/A	-52	-48	-47	N/A
6/30/2022	N/A	-46	-42	-41	N/A
3/31/2022	N/A	-37	-29	-28	N/A
12/31/2021	N/A	-26	-24	-24	N/A
9/30/2021	N/A	-20	-18	-17	N/A
6/30/2021	N/A	-16	-14	-14	N/A
3/31/2021	N/A	-12	-11	-11	N/A
12/31/2020	N/A	-9	-8	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: TYRA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: TYRA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: TYRA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: TYRA wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: TYRA wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von TYRA in 3 Jahren voraussichtlich hoch sein wird

Tyra Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 9.8% to US$27.67

Price target increased by 7.7% to US$25.20

Price target increased by 9.0% to US$24.20

Price target decreased by 9.0% to US$22.20

Price target increased by 8.4% to US$24.40

Price target decreased by 8.3% to US$19.25

Recent updates

Co-Founder notifies of intention to sell stock

Price target increased by 9.8% to US$27.67

Now 20% undervalued

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Now 21% overvalued after recent price rise

Lots Of Bullish Signals, But No Revenue Or Earnings From Tyra Biosciences

Now 22% overvalued after recent price rise

A Look At The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Price target increased by 7.7% to US$25.20

Tyra Biosciences, Inc.(NasdaqGS:TYRA) dropped from Russell 3000E Value Index

Insufficient new directors

Now 29% overvalued

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

New major risk - Revenue and earnings growth

Tyra Biosciences, Inc. Announces Board Changes

Tyra Biosciences, Inc., Annual General Meeting, May 29, 2024

Insufficient new directors

New major risk - Revenue and earnings growth

Price target increased by 9.0% to US$24.20

Co-Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Tyra Biosciences, Inc. announced that it expects to receive $200 million in funding from RA Capital Management, L.P., Boxer Capital LLC, BVF Partners L.P., Nextech Invest Ltd., OrbiMed Advisors LLC, 5AM Venture Management, LLC

New minor risk - Share price stability

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

Tyra Biosciences, Inc. Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300

Price target decreased by 9.0% to US$22.20

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Price target increased by 8.4% to US$24.40

Tyra Biosciences Announces Fda Orphan Drug Designation for Tyra-300 for the Treatment of Achondroplasia

Co-Founder exercised options and sold US$286k worth of stock

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Co-Founder & COO exercised options and sold US$350k worth of stock

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 8.3% to US$19.25

Tyra Biosciences, Inc. Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300

High number of new directors

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$20.00

Tyra Biosciences Announces Chief Financial Officer Changes

Tyra Biosciences, Inc. Announces Appointment of Ali Fawaz as General Counsel and Secretary

Tyra Biosciences GAAP EPS of -$0.36

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Tyra Biosciences, Inc.(NasdaqGS:TYRA) dropped from Russell 2000 Growth Index

High number of new directors

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

High number of new directors

Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth

Tyra Biosciences, Inc. has completed an IPO in the amount of $172.8 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken